Science Explorer Back to mapMap
Discussion
Researcher · Pharmaceutical Product Development (United States) · United States

Jai Balkissoon

Jai Balkissoon publishes mostly in Oncology, Molecular Biology and Pulmonary and Respiratory Medicine, on topics such as Cancer Treatment and Pharmacology, Angiogenesis and VEGF in Cancer and Lung Cancer Treatments and Mutations.

OpenAlex
World rank
#1,626,018
of 7,710,434 ranked researchers
Rank in United States
#505,073
of 1,627,098
Works
27
Citations
1.8k
Citations per work
67.4
h-index
15
i10-index 16Top 36% in Oncology
Jai Balkissoon

What does Jai Balkissoon research?

Jai Balkissoon's work is mostly in Medicine (44%), Biochemistry, Genetics and Molecular Biology (16%).

Health Sciences: 12 works · 44.1% of their workMedicine: 12 works · 44.1% of their workOncology: 5 works · 20.0% of their workPulmonary and Respiratory Medicine: 3 works · 10.7% of their workEndocrinology, Diabetes and Metabolism: 2 works · 6.7% of their workSurgery: 2 works · 6.7% of their workEverything else: 11 works · 39.9% of their workLife Sciences: 4 works · 16.0% of their workBiochemistry, Genetics and Molecular Biology: 4 works · 16.0% of their workMolecular Biology: 3 works · 10.7% of their workCancer Research: 1 works · 5.3% of their workTHEIR WORKJai Balkissoon27works
Life Sciences16%Health Sciences44%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1244.1%
  2. Everything else1139.9%
    1. Biochemistry, Genetics and Molecular Biology416.0%
  1. 1Oncology20% of their works
  2. 2Molecular Biology11% of their works
  3. 3Pulmonary and Respiratory Medicine11% of their works
  4. 4Endocrinology, Diabetes and Metabolism7% of their works
  5. 5Surgery7% of their works
  6. 6Cancer Research5% of their works

Research topics

Which keywords describe Jai Balkissoon's research?

The keywords of their largest research topics: Clinical Trials, Chemotherapy-Induced Peripheral Neuropathy, Taxanes, EGFR Mutations, endothelial progenitor cells, Targeted Therapy, VEGF and Hepatocellular Carcinoma.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 17 words, with their numbers
  1. Clinical Trials82 topics
  2. Chemotherapy-Induced Peripheral Neuropathy61 topic
  3. Taxanes61 topic
  4. EGFR Mutations51 topic
  5. Targeted Therapy51 topic
  6. VEGF51 topic
  7. endothelial progenitor cells51 topic
  8. Hepatocellular Carcinoma41 topic
  9. Liver Cancer41 topic
  10. Differentiated Thyroid Cancer31 topic
  11. Genomic Analysis31 topic
  12. Ovarian Cancer31 topic
  13. Thyroid Nodules31 topic
  14. Bacterial Therapy21 topic
  15. Fatty Acid Synthase21 topic
  16. Lipid Metabolism21 topic
  17. Tumor Targeting21 topic

Where does Jai Balkissoon work?

Jai Balkissoon's main affiliation in the publication record is Pharmaceutical Product Development (United States), United States.

How many publications and citations does Jai Balkissoon have?

OpenAlex counts 27 works and 1,819 citations for Jai Balkissoon, an h-index of 15, ranking #1,626,018 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Jai Balkissoon. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.